Saturday, 5 September 2026European Markets

EQVA Stock Impressive Jump On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with EQVA (EQVA.OL) jumping 15.62% to kr5.18 on Tuesday while Oslo Børs Benchmark Index_GI jumped 0.57% to kr1,424.56.

EQVA's last close was kr4.48, 12% higher than its 52-week high of kr4.00.

About EQVA

Eqva ASA, provides technical solutions and services to maritime and land based industries in Norway and internationally. It operates in three segments: Products, Solutions & Renewables; Real Estate; and Other. The company provides technical installations to the land-based and maritime industry; and develops and operates small-scale hydropower plants. It also engages in real estate business. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was incorporated in 1999 and is headquartered in Kvinnherad, Norway.

Earnings Per Share

As for profitability, EQVA has a trailing twelve months EPS of kr-0.33.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.45%.

More news about EQVA (EQVA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com